

AVXS-101 and Nusinersen for Spinal Muscular Atrophy: Effectiveness and Value

Draft Background and Scope
August 22, 2018

Background

Spinal muscular atrophy (SMA) is a rare, genetic neuromuscular disease with the most severe cases affecting infants and young children.^{1,2} SMA incidence is approximately 1 in 10,000 live births.³ The most common cause of SMA is the homozygous deletion or deletion and mutation of the alleles of the survival motor neuron 1 (*SMN1*) gene on chromosome 5q.⁴⁻⁶ *SMN1* creates SMN protein, a protein essential for motor neuron development. Although the survival motor neuron 2 (*SMN2*) gene also produces SMN protein, only a small amount of the protein it creates is functional. Hence, while the number of *SMN2* copies modulates the severity of SMA, patients without *SMN1* have an insufficient level of SMN protein regardless of the number of *SMN2* copies.⁷ This deficiency causes the irreversible degeneration of motor neurons, which leads to progressive muscle weakness and prevents patients from reaching motor milestones or retaining motor functions.¹

SMA subtypes are related to age of onset and number of motor milestones achieved (see Table 1 below).^{2,8}

Table 1. Clinical Classification of SMA

SMA Type	Age of Onset	Highest Achieved Motor Function	Natural Age of Death
0	Prenatal/ Fetal	None	<6 months
I	<6 months	Sit with support only	<2 years
II	6–18 months	Sit independently	>2 years
III	>18 months	Walk independently	Adulthood
IV	Adult (2 nd or 3 rd decade)	Walk during adulthood	Adult

Adapted from Table 1 of Verhaart *et al.* 2017.²

Type 0 SMA, the most severe subtype, affects individuals before birth and is very rare. Newborns with Type 0 have severe hypotonia (low muscle tone), need respiratory support, and have a life expectancy of minutes to weeks after birth. Type I SMA (infant-onset SMA) represents approximately 60% of all diagnosed SMA cases.³ These patients typically have two or three copies of *SMN2*, present with symptoms before six months of age, do not reach key motor milestones

(e.g., sitting without support), and lose motor functions over time. Pulmonary complications are common, often leading to respiratory support. Patients may die or need permanent respiratory support within two years of life.³ Approximately 40% of patients diagnosed with SMA have Type II or Type III.³ Type II SMA presents between 6 to 18 months of age with patients typically having three copies of *SMN2*. These patients cannot walk independently, and most patients survive to adulthood with aggressive supportive care.³ Type III SMA presents in patients aged 18 months to 18 years, and patients typically have three or four copies of *SMN2*. Patients have a normal life expectancy and can walk independently, although they may lose this ability over time. Type IV SMA, a very rare and the least severe subtype, presents in adults. Adults with Type IV SMA typically retain the ability to walk independently, do not suffer from respiratory issues, and have a normal life expectancy.^{2,8}

Patients with SMA may need intensive care and support, especially those with SMA Type II. To maintain mobility and function as long as possible, multidisciplinary, supportive care including respiratory, nutritional, gastrointestinal, orthopedic, and other support is needed.⁹⁻¹¹ Nevertheless, supportive care does not modify disease progression and patients may be entirely dependent on family members and caregivers. The intense care and physical effort involved with caring for a patient with SMA may cause loss of sleep, stress, anxiety, and emotional distress for caregivers.^{12,13} Hence, SMA may affect the health-related quality of life of patients as well as their families and caregivers.

Currently, only one disease-modifying therapy (nusinersen, Spinraza[®], Biogen Idec) has been approved to treat SMA.¹⁴ Nusinersen, an antisense oligonucleotide, targets the *SMN2* gene so that it creates more functional SMN protein. It is administered via intrathecal injection with four loading doses (day 0, day 14, day 28, and day 63) and every four months thereafter. Nusinersen has been studied in patients with or likely to develop SMA Types I-III,¹⁵⁻¹⁷ with several studies on-going.^{15,18-20} In December 2016, the Food and Drug Administration (FDA) approved nusinersen for the treatment of 5q SMA (any subtype).¹⁴

A new, systemic gene therapy (AVXS-101, Novartis/AveXis) is currently in development to treat patients with SMA. AVXS-101 uses the adeno-associated virus serotype 9 vector to deliver a copy of the *SMN* gene to replace the missing *SMN* gene.²¹ AVXS-101 is being studied as a one-time, intravenous administration. The FDA granted AVXS-101 a Breakthrough Therapy Designation and Fast Track Designation, with an FDA decision expected in early 2019.²² The potential use of AVXS-101 has generated interest from clinicians, patients, and their families especially since SMA was recently added to the list of conditions for which to screen all newborns in the US.²³ Nevertheless, uncertainties remain regarding the effectiveness of AVXS-101 and nusinersen compared with supportive care and with each other, and how well the potential cost of these interventions aligns with potential patient benefits. Therefore, stakeholders will benefit from a comprehensive review

of the clinical evidence on both drugs and an analysis of their long-term cost-effectiveness and potential budget impact.

Stakeholder Input

This draft scoping document was developed with input from diverse stakeholders, including patients and their families, clinicians, researchers, and manufacturers of the agents of focus in this review. This document incorporates feedback gathered during preliminary calls with stakeholders and open input submissions from the public.

From caregivers, we heard how devastating the diagnosis of Type I SMA can be and how difficult it is to watch the disease progress in a child. Care entails approaches to preserve respiratory and muscle function, including physical therapy, nutritional support, and extensive medical equipment. From adults with SMA, we also heard how frustrating it is that new interventions have not been commonly studied in adults and that more data are needed in this population, including appropriate dosages.

A final scoping document will be posted following a three-week public comment period. ICER looks forward to continued engagement with stakeholders throughout its review and encourages comments to refine our understanding of the clinical effectiveness and value of these agents.

Report Aim

This project will evaluate the health and economic outcomes of AVXS-101 and nusinersen for patients with SMA. We propose to assess AVXS-101 and nusinersen under an adaptation of the ICER value framework focused on treatments for serious, ultra-rare conditions because we believe the assessment meets the following proposed criteria:

- The eligible patient populations for the treatment indication(s) included in the scope of the ICER review is estimated at fewer than approximately 10,000 individuals.^{2,3}

- There are no ongoing or planned clinical trials of the treatment for a patient population greater than approximately 10,000 individuals.

We encourage all stakeholders to submit comments about selecting this approach. The ICER value framework for ultra-rare conditions includes both quantitative and qualitative comparisons across treatments to ensure that the full range of benefits and harms – including those not typically captured in the clinical evidence such as innovation, public health effects, reduction in disparities, and unmet medical needs – are considered in the judgments about the clinical and economic value of the interventions.

Scope of Clinical Evidence Review


The proposed scope for this assessment is described on the following pages using the PICOTS (Population, Intervention, Comparators, Outcomes, Timing, and Settings) framework. Evidence will be abstracted from randomized controlled trials and non-randomized studies as well as high-quality systematic reviews; high-quality comparative cohort studies will be considered, particularly for long-term outcomes and uncommon adverse events. Our evidence review will include input from patients and patient advocacy organizations, data from regulatory documents, information submitted by manufacturers, and other grey literature when the evidence meets ICER standards (for more information, see <https://icer-review.org/methodology/icers-methods/icer-value-assessment-framework/grey-literature-policy/>).

All relevant evidence will be synthesized qualitatively or quantitatively. Wherever possible, we will seek out head-to-head studies of the interventions and comparators of interest. Full details regarding the literature search, screening strategy, data extraction, and evidence synthesis will be provided after the finalized scope in a research protocol published on the Open Science Framework website (<https://osf.io/7awvd/>).

Analytic Framework

The general analytic framework for assessment of AVXS-101 and nusinersen is depicted in Figure 1 on the following page.

Figure 1. Analytic Framework: Treatments for Spinal Muscular Atrophy



SMA: spinal muscular atrophy

The diagram begins with the population of interest on the left. Actions, such as treatment, are depicted with solid arrows which link the population to outcomes. For example, a treatment may be associated with specific health outcomes. Outcomes are listed in the shaded boxes; those within the rounded boxes are intermediate outcomes (e.g., use of ventilatory support), and those within the squared-off boxes are key measures of benefit (e.g., mortality). The key measures of benefit are linked to intermediate outcomes via a dashed line, as the relationship between these two types of outcomes may not always be validated. Curved arrows lead to the adverse events of treatment which are listed within the blue ellipsis.²⁴

Populations

The population of focus for the review is infants, children, and adults with SMA. Where possible, we will look at subgroup data defined by age of onset (including presymptomatic SMA) or SMA subtype (0-IV).

Interventions

The list of interventions was developed with input from patient organizations, clinicians, manufacturers, and payers on which drugs to include. The full list of interventions is as follows:

- Nusinersen
- AVXS-101

We will work further with clinical experts to define likely pathways of care with these agents, including the possibility of sequential use.

Comparators

Where data permit, we intend to compare the agents to each other and to supportive care (with or without placebo). It is unlikely that all comparisons will be available for all populations and subpopulations defined above, and we will note where gaps in evidence exist.

Outcomes

The outcomes of interest are described below.

Efficacy:

- Mortality
- Permanent invasive ventilatory support
- Motor function, including:
 - Hammersmith Functional Motor Scale-Expanded (HFMSE)
 - Hammersmith Infant Neurological Examination-Section 2 (HINE-2)
 - Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)
 - Revised Upper Limb Module (RULM)
 - World Health Organization motor development milestones (sitting without support, standing with assistance, hands-and-knees crawling, walking with assistance, standing alone, walking alone)
- Mobility (e.g., 6-Minute Walk Test)
- Use of respiratory or gastrointestinal support
- Other complications of SMA (e.g., scoliosis)
- Quality of Life (e.g., PedsQoL)

Safety:

- Serious adverse events
- Adverse events leading to discontinuation
- Treatment-related adverse events
- Injection or infusion site reactions

Timing

Evidence on intervention effectiveness and safety will be derived from studies of any duration.

Settings

All settings will be considered, with a focus on settings in the United States.

Potential Other Benefits and Contextual Considerations

Our review seeks to provide information on potential other benefits offered by the intervention to the individual patient, caregivers, the delivery system, other patients, or the public that would not have been considered as part of the evidence on comparative clinical effectiveness. These elements are listed in Table 2 below.

Table 2. Potential Other Benefits and Contextual Considerations

Potential Other Benefits
This intervention offers reduced complexity that will significantly improve patient outcomes.
This intervention will reduce important health disparities across racial, ethnic, gender, socio-economic, or regional categories.
This intervention will significantly reduce caregiver or broader family burden.
This intervention offers a novel mechanism of action or approach that will allow successful treatment of many patients for whom other available treatments have failed.
This intervention will have a significant impact on improving the patient’s ability to return to work and/or their overall productivity.
This intervention will have a significant positive impact outside the family, including communities.
This intervention will have a significant impact on the entire “infrastructure” of care, including effects on screening for affected patients, on the sensitization of clinicians, and on the dissemination of understanding about the condition, that may revolutionize how patients are cared for in many ways that extend beyond the treatment itself.
Other important benefits or disadvantages that should have an important role in judgments of the value of this intervention.
Potential Other Contextual Considerations
This intervention is intended for the care of individuals with a condition of particularly high severity in terms of impact on length of life and/or quality of life.
This intervention is intended for the care of individuals with a condition that represents a particularly high lifetime burden of illness.
This intervention is the first to offer any improvement for patients with this condition.
Compared to best supportive treatment, there is significant uncertainty about the long-term risk of serious side effects of this intervention.
Compared to best supportive treatment, there is significant uncertainty about the magnitude or durability of the long-term benefits of this intervention.
There are additional contextual considerations that should have an important role in judgments of the value of this intervention.

ICER encourages stakeholders to provide input on these elements in their public comment submissions.

Scope of Comparative Value Analyses

As a complement to the evidence review, we will develop an economic model to assess the lifetime cost-effectiveness of each treatment of interest relative to comparator interventions. We plan to evaluate AVXS-101, nusinersen, and supportive care in infants, children, and adults (pending data availability) with SMA. Where possible, we will look at cost-effectiveness by subgroups defined by SMA subtype, symptomatic status (i.e. pre-symptomatic or symptomatic) and disease onset (i.e. early or late onset).

We will develop a Markov model which will be based in part on a literature review of prior published models of SMA and health technology assessment reports of SMA in other jurisdictions such as England,¹² Canada,²⁵ Ireland,²⁶ Scotland,²⁷ and Australia.²⁸ Following the ICER methodology for treatments of ultra-rare conditions, we will investigate the modified societal costs in relation to health sector costs and consider whether the findings suggest the need for a dual base case perspective: "When the impact of treatment on patient and caregiver productivity, education, disability, and nursing home costs is substantial and these costs are large in relation to health care costs, ICER will present its base case health system perspective model results in tandem with the results of a scenario analysis inclusive of broader societal costs."

The Markov model will consist of health states based on motor function milestones, and an absorbing state, death. A cohort of patients will transition between the health states over a lifetime horizon, i.e., the patients will be modeled from treatment initiation until death. A 3% annual discount rate will be applied to both costs and outcomes.

Key model inputs will include clinical transition probabilities, quality of life values, and health care costs. Probabilities, costs, and other inputs may differ between the interventions to reflect the effectiveness between interventions. Treatment effects will be estimated using results from relevant trials identified in the clinical review. Uncertainty in the model parameters will be captured using one-way sensitivity analyses and parametric distributions which will inform probabilistic analyses. We will also include relevant scenario analyses as applicable.

Health outcomes will be dependent on time spent in each health state, clinical events, and adverse events (AEs). Quality of life weights will be applied to each health state, including quality of life decrements for serious AEs. The health outcome of each intervention will be evaluated in terms of life-years and quality-adjusted life years (QALYs) gained. The model will include direct medical costs, including but not limited to costs related to intervention administration, monitoring, SMA-related care, and serious AEs. Additionally, patient and caregiver productivity losses will also be included in the societal analysis. Given the known caregiver burden associated with SMA, we may model caregiver-related quality of life in addition to costs in the societal analysis, pending data availability. For all analyses, relevant pairwise comparisons will be made between treatments, and

fully incremental analysis will be performed. Results will be expressed in terms of the marginal cost per QALY gained, cost per life-year gained, and cost per selected clinical outcomes.

In separate analyses, we will explore the potential health system budgetary impact of treatment with both agents over a five-year time horizon. We will analyze potential budget impact of AVXS-101 versus nusinersen, and the impact of both agents (if prices are known) versus best supportive care. We will utilize published or otherwise publicly-available information on the potential population eligible for treatment and the results from the economic model for treatment costs and cost offsets. This budgetary impact analysis will indicate the relation between treatment prices and level of use for a given potential budget impact and will allow assessment of any need for managing the cost of such interventions. More information on ICER's methods for estimating potential budget impact can be found at: <http://icer-review.org/wp-content/uploads/2018/05/ICER-value-framework-v1-21-18.pdf>.

Identification of Low-Value Services

As described in its Final Value Assessment Framework for 2017-2019, ICER will now include in its reports information on wasteful or lower-value services in the same clinical area that could be reduced or eliminated to create additional resources in health care budgets for higher-value innovative services (for more information, see <https://icer-review.org/material/final-vaf-2017-2019/>). These services are ones that would not be directly affected by nusinersen or AVXS-101 (e.g., less need for respiratory support), as these services will be captured in the economic model. Rather, we are seeking services used in the current management of SMA beyond the potential offsets that arise from a new intervention. ICER encourages all stakeholders to suggest services (including treatments and mechanisms of care) that could be reduced, eliminated, or made more efficient.

References

1. Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. *Lancet Neurol.* 2012;11(5):443-452.
2. Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. *Orphanet J Rare Dis.* 2017;12(1):124.
3. Lally C, Jones C, Farwell W, Reyna SP, Cook SF, Flanders WD. Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States. *Orphanet J Rare Dis.* 2017;12(1):175.
4. Brzustowicz LM, Lehner T, Castilla LH, et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. *Nature.* 1990;344(6266):540-541.
5. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. *Cell.* 1995;80(1):155-165.
6. Wirth B, Herz M, Wetter A, et al. Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. *Am J Hum Genet.* 1999;64(5):1340-1356.
7. Butchbach ME. Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases. *Front Mol Biosci.* 2016;3:7.
8. Russman BS. Spinal muscular atrophy: clinical classification and disease heterogeneity. *J Child Neurol.* 2007;22(8):946-951.
9. Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. *Neuromuscul Disord.* 2018;28(3):197-207.
10. Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. *Neuromuscul Disord.* 2018;28(2):103-115.
11. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. *J Child Neurol.* 2007;22(8):1027-1049.
12. NICE. *Single Technology Appraisal - Nusinersen for treating spinal muscular atrophy [ID1069] - Committee Papers.* National Institute for Health and Care Excellence (NICE);2018.
13. Qian Y, McGraw S, Henne J, Jarecki J, Hobby K, Yeh WS. Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: a qualitative study. *BMC Neurol.* 2015;15:217.
14. Food and Drug Administration. Spinraza (nusinersen) injection, for intrathecal use [package insert]. 2016.
15. Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. *Lancet.* 2016;388(10063):3017-3026.
16. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. *N Engl J Med.* 2017;377(18):1723-1732.
17. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. *N Engl J Med.* 2018;378(7):625-635.
18. Ascadi G, et al. Safety and Efficacy of Nusinersen in Infants/Children With Spinal Muscular Atrophy (SMA): Part 1 of the Phase 2 EMBRACE Study. Paper presented at: Presented at the 22nd International Annual Congress of the World Muscle Society 2017; Saint Malo, France.

19. Castro D, et al. Longer-term Assessment of the Safety and Efficacy of Nusinersen for the Treatment of Infantile-Onset Spinal Muscular Atrophy (SMA): An Interim Analysis of the SHINE Study. Paper presented at: Presented at AAN2018; Los Angeles, CA.
20. De Vivo DC, et al. Nusinersen in Presymptomatic Infants with Spinal Muscular Atrophy: Interim Efficacy and Safety Results from Phase 2 of NURTURE Study. Presented at the CureSMA Conference; 2018; Dallas, TX.
21. Mendell JR, Al-Zaidy S, Shell R, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *N Engl J Med*. 2017;377(18):1713-1722.
22. Novartis AG. Q2 2018 Results: Investor Presentation. 2018; <https://www.novartis.com/investors>.
23. Department of Health and Human Services. Recommended Uniform Screening Panel (July 2018). 2018; <https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/index.html>. Accessed 8/22/2018.
24. Woolf S. An organized analytic framework for practice guideline development: using the analytic logic as a guide for reviewing evidence, developing recommendations, and explaining the rationale. In: McCormick K, Moore S, Siegel R, eds. *Methodology Perspectives*. Vol AHCPR Pub. No. 95-0009. Rockville, MD: Agency for Health Care Policy and Research; 1995:105-113.
25. CADTH. *Pharmacoeconomic Review Report - Nusinersen for treatment of patients with 5q SMA*. Canadian Agency for Drugs and Technologies in Health (CADTH);2018.
26. NCPE. *Cost-effectiveness of Nusinersen (Spinraza) for the treatment of 5q spinal muscular atrophy (SMA)*. National Centre for Pharmacoeconomics (NCPE);2018.
27. SMC. *Nusinersen for the treatment of 5q spinal muscular atrophy (SMA)*. Scottish Medicines Consortium (SMC);2018.
28. PBAC. *Nusinersen for spinal muscular atrophy (SMA) - Public Summary Document - Pharmaceutical Benefits Advisory Committee (PBAC) November 2017 Meeting*. Pharmaceutical Benefits Advisory Committee (PBAC);2018.